# A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

> **NCT02297425** · PHASE2 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC

## Interventions

- **DRUG:** PF-06459988

## Key facts

- **NCT ID:** NCT02297425
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-01
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02297425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02297425, "A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT02297425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*